Akcea Therapeutics is returning to its parent company, Ionis Pharmaceuticals, in a $500 million deal that brings an end to a tumultuous three years as a standalone company.
The definitive agreement announced Monday calls for Carlsbad, CA-based Ionis (NASDAQ: IONS) to pay $18.15 for each share of Akcea (NASDAQ: AKCA) that it does not already own. That price is a 60 percent premium to the Boston-based company’s closing stock price on Friday.
Akcea develops drugs for rare diseases. The company currently has two commercialized products, along with others in its pipeline, some of which are in development with large... Read more »
Author: Frank Vinluan
Date : 2020-08-31T18:37:36.000Z